Upregulation of the 2-5A synthetase/rnase l antiviral pathway associated with chronic fatigue syndrome

Clinical Infectious Diseases

Volumn 18, Issue , 1994, Pages S96-S104

  Suhadolnik, Robert J ^a,b,c,d,e   Reichenbach, Nancy L ^a,b,c,d,e   Hitzges, Patricia ^a,b,c,d,e   Sobol, Robert W ^a,b,c,d,e   Peterson, Daniel L ^a,b,c,d,e   Henry, Berch ^a,b,c,d,e   Ablashi, Dharam V ^a,b,c,d,e   Müller, Werner E G ^a,b,c,d,e   Schröder, Heinz C ^a,b,c,d,e   Carter, William A ^a,b,c,d,e   Strayer, David R ^a,b,c,d,e  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CFS Clinic at Incline Village ^*  (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; IMMUNOMODULATING AGENT; RIBONUCLEASE;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME BLOOD LEVEL; ENZYME REGULATION; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADENINE NUCLEOTIDES; ANTIVIRAL AGENTS; ENDORIBONUCLEASES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMAN; MALE; MIDDLE AGE; OLIGORIBONUCLEOTIDES; POLY I-C; POLY U; RNA, DOUBLE-STRANDED; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; UP-REGULATION; VIRUS DISEASES;

EID: 0028084853     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/18.Supplement_1.S96     Document Type: Article

References (61)

1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108:387-9.
2. Schluederberg A, Straus SE, Peterson P, et al. Chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med 1992;117:325-31.
3. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991; 13(suppl 1):S8-11.
4. Josephs SF, Henry B, Balachandran N, et al. HHV-6 reactivation in chronic fatigue syndrome [letter]. Lancet 1991;337:1346-7.
5. Balachandran N, Amelse RE, Zhou WW. Chang CK. Identification of proteins specific for human herpesvirus 6-infected human T cells. J Virol 1989;63:2835-40.
6. Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116: 103-13.
7. Peterson DL, Strayer DR, Bastien S, et al. Clinical improvements obtained with Ampligen in patients with severe chronic fatigue syndrome and associated encephalopathy. In: Hyde B, ed. The clinical and scientific basis of myalgic encephalomyelitis/chronic fatigue syndrome. Ottawa: Nightingale Research Foundation, 1992:634-8.
8. Strayer DR, Gillespie D, Carter WA, et al. Long term improvements in patients with the CDC case definition of chronic fatigue syndrome treated with Ampligen. Journal ofChronic Fatigue Syndromes, 1994 (in press).
9. Ablashi DB, Zompetta C, Lease C, et al. Human herpesvirus-6 (HHV-6) and chronic fatigue syndrome (CFS). Can Dis Wkly Rep 1991; 17SI:33-7.
10. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985;102:1-7.
11. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985;102:7-16.
12. Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle D. Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med 1988;81:326-9.
13. Yousef GE, Bell EJ, Mann GF, et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1988;1:146-50.
14. Cunningham L, Bowles NE, Lane RJM, Dubowitz V, Archard LC. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol 1990;71: 1399-402.
15. Gow JW, Behan WMH, Clements GB, Woodall C, Riding M, Behan PO. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. Br Med J 1991;302:692-6.
16. DeFreitas E, Hilliard B, Cheney PR, et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci USA 1991;88:2922-6.
17. Khan AS, Heneine WM, Chapman LE, et al. Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med 1993;118:241-5.
18. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988;157:405-12.
19. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991:73:1224-34.
20. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991;338:707-12.
21. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987;139:3306-13.
22. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28: 1403-10.
23. Behan PO, Behan WMH, Bell EJ. The postviral fatigue syndrome—an analysis of the findings in 50 cases. J Infect 1985; 10:211-22.
24. Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman RB. Low natural killer syndrome: clinical and immunologic features. Natural Immunity and Cell Growth Regulation 1987;6:116-28.
25. Borysiewicz LK, Haworth SJ, Cohen J, Mundin J, Rickinson A, Sissons JGP. Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. Q J Med [NewSer] 1986;58:111-21.
26. Straus SE, Dale JK, Peter JB, Dinarello CA. Circulating lymphokine levels in the chronic fatigue syndrome [letter], J Infect Dis 1989;160:1085-6.
27. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. N Engl J Med 1988;319:1692-8.
28. Strayer DR, Brodsky I, Pequignot EC, et al. The antitumor activity of Ampligen, a mismatched double-stranded RNA, which modulates the 2-5A synthetase/RNase L pathway in cancer and AIDS. In: Dia-sio RB, Sommadossi J-P. eds. Advances in the chemotherapy of AIDS. New York: Pergamon Press, 1990:23-31.
29. Haines DS, Strauss KI, Gillespie DH. Cellular response to double stranded RNA. J Cell Biochem 1991;46:9-20.
30. Lacour J. Clinical trials using polyadenylic-polyuridylic acid as an adjusant to surgery in treating different human tumors. Journal of Biological Response Modifiers 1985;4:538-43.
31. Laurent-Crawford AG, Krust B, de Paillette ED, Montagnier L, Hovanessian AG. Antiviral action of polyadenylic-polyuridylic acid against HIV in cell cultures. AIDS Res Hum Retroviruses 1992;8:285-90.
32. Brodsky I, Strayer DR, Krueger LJ, Carter WA. Clinical studies with Ampligen (mismatched double-stranded RNA). Journal of Biological Response Modifiers 1985;4:669-75.
33. Carter WA, Strayer DR, Hubbell HR, Brodsky 1. Preclinical studies with Ampligen (mismatched double-stranded RNA). Journal of Biological Response Modifiers 1985;4:495-502.
34. Carter WA, Hubbell HR, Krueger LJ, Strayer DR. Comparative studies of Ampligen (mismatched double-stranded RNA) and interferons. Journal of Biological Response Modifiers 1985;4:613-20.
35. Zarling JM, Schlais J, Eskra L, Greene JJ, Ts’o POP, Carter WA. Augmentation of human natural killer cell activity by polyinosinic acid-polycytidylic acid and its nontoxic mismatched analogues. J Immunol 1980;124:1852-7.
36. Wiltrout RH, Salup RR, Twilley TA, Talmadge JE. Immunomodulation of natural killer activity by polyribonucleotides. Journal of Biological Response Modifiers 1985;4:512-7.
37. Pinto AJ, Morahan PS, Brinton MA. Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses, Int J Immunopharmacol 1988;10:197-209.
38. Carter WA, Strayer DR, Brodsky I, et al. Clinical, immunological, and virological effects of Ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1987;1:1286-92.
39. Strayer DR, Carter WA, Pequignot E, et al. Activity of a synthetic dsRNA—Ampligen—in HIV disease. Clinical Biotechnology 1991;3:169-75.
40. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem 1982;51:251-82.
41. Katze MG, Agy MB. Regulation of viral and cellular RNA turnover in cells infected by eukaryotic viruses including HIV-1. Enzyme 1990;44:332-46.
42. Cayley PJ, Knight M, Kerr IM. Virus-mediated inhibition of the ppp(A2'p)nA system and its prevention by interferon. Biochem Biophys Res Commun 1982;104:376-82.
43. Schattner A, Wallach D, Merlin G, Hahn T, Levin S, Revel M. Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 1981;2:497-500.
44. Suhadolnik RJ, Flick MB, Mosca JD, Sawada Y, Doetsch PW. Vonderheid EC. 2', 5'-01igoadeny!ate synthetase from cutaneous T-cell lymphoma: biosynthesis, identification, quantitation, molecular size of the 2', 5'-oligoadenylates, and inhibition of protein synthesis. Biochemistry 1983;22:4153-8.
45. Suhadolnik RJ, Reichenbach NL, Lee C, Strayer DR, Brodsky I, Carter WA. Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase. 2-5A oligomer size and natural killer cell activity associated with antitumor response clinically. In: Williams BRG, Silverman RH, eds. The 2-5A system: molecular and clinical aspects of the interferon-regulated pathway. New York: Alan R. Liss. 1985:449-65.
46. Vonderheid EC, Suhadolnik RJ, Sobel EL, Flick MB, Mosca JD. Increased 2', 5'-oligoadenylate synthetase activity in blood mononuclear leukocytes from patients with advanced cutaneous T-cell lymphoma. Clin Immunol Immunopathol 1984;31:138-50.
47. Fronko GE, Suhadolnik RJ, Vonderheid EC, et al. Decreased Epstein-Barr virus-induced transformation, and elevated 2-5A synthetase and RNase L activity in peripheral blood mononuclear cells from patients treated with recombinant interferon alpha 2b. Biochem Biophys Res Commun 1988;153:448-53.
48. Suhadolnik RJ, Reichenbach NL, Sobol RW, et al. Biochemical defects in the 2-5A synthetase/RNase L pathway associated with chronic fatigue syndrome with encephalopathy. In: Hyde B, ed. The clinical and scientific basis of myalgic encephalomyelitis/chronic fatigue syndrome. Ottawa: Nightingale Research Foundation, 1992:613-7.
49. Li SW, Moskow JJ, Suhadolnik RJ. 8-Azido double-stranded RNA photoaffinity probes. Enzymatic synthesis, characterization, and biological properties of poly(I, 8-axidoI)-poly(C) and poly(l, 8-azidol)-poly(C12U) with 2', 5'-oligoadenylate synthetase and protein kinase. J Biol Chem 1990;265:5470-4.
50. Khanna KK, An S, Wu JM. Landolfo S, Hovanessian AG. Absence of the 40-kDa form of (2'-5')oligoadenylate synthetase and its corresponding mRNA from skin fibroblasts derived from Alzheimer disease patients. Proc Natl Acad Sci USA 1991;88:5852-6.
51. Wreschner DH, James TC, Silverman RH, Kerr IM. Ribosomal RNA cleavage, nuclease activation and 2-5A (ppp(A2’p)nA) in interferon-treated cells. Nucleic Acids Res 1981;9:1571-81.
52. Revel M. Molecular mechanisms involved in the antiviral effects of interferon. In: Gresser I, ed. Interferon 1979. Vol I. London: Academic Press, 1979:101-63.
53. Williams BRG, Read SE, Freedman MH, Carver DH, Gelfand EW. The assay of 2-5A synthetase as an indicator of interferon activity and virus infection in vivo. In: Merigan TC, Friedman RM, eds. Interferons (UCLA symposia on molecular and cellular biology). Vol 25. New York: Academic Press, 1982:253-67.
54. Schattner A, Merlin G, Wallach D, et al. Monitoring of interferon therapy by assay of (2'-5')oligo-isoadenylate synthetase in human peripheral white blood cells. J Interferon Res 1981;1:587-94.
55. Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston Ml. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983;157:2140-6.
56. Ablashi DV, Balachandran N, Josephs SF, et al. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates. Virology 1991;184:545-52.
57. Saxinger C, Polesky H, Eby N, et al. Antibody reactivity with HBLV (HHV-6) in U.S. populations. J Virol Methods 1988;21:199-208.
58. Samanta H, Dougherty JP, Lengycl P. Synthesis of (2-5') (A)n from ATP: characteristics of the reaction catalyzed by (2'-5') (A)n synthetase purified from mouse Ehrlich ascites tumor cells treated with interferon. J Biol Chem 1980;255:9807-13.
59. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I) • poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994; 18(suppl 1):S88-95.
60. Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1989;151:122-4.
61. Stewart WE II. The interferon system. New York: Springer Verlag, 1979:257-65.